A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly

References

• World Health Organization. Children: reducing mortality. 2013; Available from: http://www.who.int/mediacentre/factsheets/fs178/en/
   Google Scholar
• Centres for Disease Control and Prevention. Pneumococcal disease, risk factors. 2014; Available from: http://www.cdc.gov/pneumococcal/about/risk-transmission.html
   Google Scholar
• Centres for Disease Control and Prevention, Active Bacterial Core Surveillance (ABC's) report: Emerging Infection Program Network, Streptococcus pneumoniae Surveillance Report, 2012.
   Google Scholar
• Morrow A, De Wals P, Petit G, Guay M, Erickson LJ. The burden of pneumococcal disease in the canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol 2007; 18 2:121-7; PMID:18923713
   PubMed Web of Science ®Google Scholar
• The Australian Immunisation Handbook, Australaian Government, Department of Health and Aging, 2013; 10-th Edition.
   Google Scholar
• Scott JAG, Hall AJ. The value and complications of percutaneous transthoracic lung aspiration for the etiologic diagnosis of community-acquired pneumonia. Chest 1999; 116 6:1716-32; PMID:10593800; http://dx.doi.org/10.1378/chest.116.6.1716
   PubMedGoogle Scholar
• Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database System Rev 2013; 1: Art. no. CD000422; PMID:23440780; http://dx.doi.org/10.1002/14651858.CD000422.pub3
   PubMedGoogle Scholar
• Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the united states incorporating herd effects. Pediatr Infect Dis J 2006; 25 6:494-501; PMID:16732146; http://dx.doi.org/10.1097/01.inf.0000222403.42974.8b
   PubMed Web of Science ®Google Scholar
• Musher DM. Editorial commentary: Should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults? Clin Infect Dis 2012; 55 2:265-7; PMID:22495544; http://dx.doi.org/10.1093/cid/cis364
   PubMedGoogle Scholar
• MacIntyre CR, Ridda I, Gao Z, Moa AM, McIntyre PB, Sullivan JS, Jones TR, Hayen A, Lindley RI. A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly. PLoS ONE 2014; 9 4; PMID:24760002; http://dx.doi.org/10.1371/journal.pone.0094578
   PubMedGoogle Scholar
• De Roux A, Schmöle, Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, Baker SA, Razmpour A, Emini EA, Fernsten PD., et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46 7:1015-23; PMID:18444818; http://dx.doi.org/10.1086/529142
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Harnden S, Burton RL, Albert RK, Bailey WC, Casaburi R, Connett J, Cooper JA, Criner GJ, Curtis JL., et al. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin Infect Dis 2012; 55 5:e35-44; PMID:22652582; http://dx.doi.org/10.1093/cid/cis513
   PubMedGoogle Scholar
• Jackson LA, Neuzil KM, Nahm MH, Whitney CG, Yu O, Nelson JC, Starkovich PT, Dunstan M, Carste B, Shay DK., et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007; 25 20:4029-4037; PMID:17391816; http://dx.doi.org/10.1016/j.vaccine.2007.02.062
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, Pebody R, Miller E. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009; 49 9:1318-25; PMID:19814624; http://dx.doi.org/10.1086/606046
   PubMed Web of Science ®Google Scholar
• Lazarus, R, Clutterbuck E, Yu LM, Bowman J, Bateman EA, Diggle L, Angus B, Peto TE, Beverley PC, Mant D., et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 2011; 52 6:736-42; PMID:21367726; http://dx.doi.org/10.1093/cid/cir003
   PubMed Web of Science ®Google Scholar
• Baxendale HE, Keating SM, Johnson M, Southern J, Miller E, Goldblatt D. The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. Vaccine 2010; 28 30:4763-70; PMID:20471437; http://dx.doi.org/10.1016/j.vaccine.2010.04.103
   PubMed Web of Science ®Google Scholar
• Ridda I, Macintyre CR, Lindley R, Gao Z, Sullivan JS, Yuan FF, McIntyre PB. Immunological responses to pneumococcal vaccine in frail older people. Vaccine 2009; 27 10:1628-36; PMID:19100304; http://dx.doi.org/10.1016/j.vaccine.2008.11.098
   PubMed Web of Science ®Google Scholar
• Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, Peters HV, Knutsen B, Hickel J, Parkinson AJ. Immunogenicily and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age. Clin Infect Dis 2009; 49 2:241-8; PMID:19522655; http://dx.doi.org/10.1086/599824
   PubMed Web of Science ®Google Scholar
• Musher DM., Rueda AM, Nahm MH, Graviss EA, Rodriguez, Barradas MC., Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008; 198 7:1019-27; PMID:18710324; http://dx.doi.org/10.1086/591629
   PubMed Web of Science ®Google Scholar
• Hak E, Grobbee DE, Sanders EA, Verheij TJ, Bolkenbaas M, Huijts SM, Gruber WC, Tansey S, McDonough A, Thoma B., et al. Rationale and design of CAPITA: A RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med, 2008; 66 9:378-83; PMID:18990781
   PubMed Web of Science ®Google Scholar
• Bonten M, Bolkenbaas M, Huijts S, Webber C, Gault S, Gruber W, Grobbee D. Community Acquired Pnuemonia Immunisation Trial in Adults (CAPITA), in 9-th International Symposium on Pneumococci and Pneumococcal Disease, ISPPD-9. 2014; Hyderabad, India. p. 95.
   Google Scholar
• Falagas, ME, Pitsouni EI, Malietzis GA, Pappas G. Comparison of pubmed, scopus, web of science, and google scholar: strengths and weaknesses. FASEB J 2008; 22 2:338-42; PMID:17884971; http://dx.doi.org/10.1096/fj.07-9492LSF
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. 2005; Oxford.
   Google Scholar
• Smith KJ, Wateska AR, Nowalk MP, Raymund M, Lee BY, Zimmerman RK., Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in US older adults. Am J Prev Med 2013; 44 4:373-81; PMID:23498103; http://dx.doi.org/10.1016/j.amepre.2012.11.035
   PubMed Web of Science ®Google Scholar
• Weycker D., Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA., Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine 2012; 30 36:5437-44; PMID:22728289; http://dx.doi.org/10.1016/j.vaccine.2012.05.076
   PubMed Web of Science ®Google Scholar
• Smith KJ, Nowalk MP, Raymund M, Zimmerman RK. Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults. Vaccine 2013; 31 37:3950-6; PMID:23806240; http://dx.doi.org/10.1016/j.vaccine.2013.06.037
   PubMed Web of Science ®Google Scholar
• Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012; 307 8:804-12; PMID:22357831; http://dx.doi.org/10.1001/jama.2012.169
   PubMed Web of Science ®Google Scholar
• Cho BH, Stoecker C, Link, Gelles R, Moore MR. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine 2013; 31 50:6011-21; PMID:24148572; http://dx.doi.org/10.1016/j.vaccine.2013.10.024
   PubMed Web of Science ®Google Scholar
• Boccalini S, Bechini A, Levi M, Tiscione E, Gasparini R, Bonanni P. Cost-effectiveness of new adult pneumococcal vaccination strategies in italy. Hum Vaccin Immunother 2013; 9 3:699-706; PMID:23295824; http://dx.doi.org/10.4161/hv.23268
   PubMed Web of Science ®Google Scholar
• Liguori, G, Parlato A2, Zamparelli AS3, Belfiore P1, Gallé F1, Di Onofrio V1, Riganti C4, Zamparelli B5. Società Italiana di Health Horizon Scanning (SIHHS). Adult immunization with 13-valent pneumococcal vaccine in campania region, south italy: an economic evaluation. Hum Vaccin Immunother 2014; 10 2:492-7; PMID:24185467; http://dx.doi.org/10.4161/hv.26888
   PubMed Web of Science ®Google Scholar
• Rozenbaum, MH, van Hoek AJ, Fleming D, Trotter CL, Miller E, Edmunds WJ. Vaccination of risk groups in england using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ 2012; 345 7882: PMID:23103369; 10.1136/bmj.e6879
   PubMedGoogle Scholar
• Rozenbaum MH, Hak E, van der Werf TS, Postma MJ. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged ≥65 years in the netherlands. Clin Ther 2010; 32 8:1517-32; PMID:20728764; http://dx.doi.org/10.1016/j.clinthera.2010.06.016
   PubMed Web of Science ®Google Scholar
• Pradas R, Gil de Miguel A, Álvaro A, Gil, Prieto R, Lorente R, Méndez C, Guijarro P, Antoñanzas F., Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old spanish cohort using a dynamic model. BMC Infect Dis 2013; 13 1:175; PMID:23578307; http://dx.doi.org/10.1186/1471-2334-13-175
   PubMedGoogle Scholar
• Centres for Disease Control and Prevention. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59 34:1102-6; PMID:20814406
   PubMedGoogle Scholar
• Centres for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations fo the advisory committee on immunisation practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012; 61 40:816-9; PMID:23051612
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children–advisory committee on immunization practices (ACIP), 2010. Morbidity and Mortality Weekly Report 2010; 59 9:258-61; PMID:20224542
   PubMedGoogle Scholar
• Public Helath England. General information on pneumococcal disease. 2013; Available from: http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1203008864027
   Google Scholar
• Briggs A, Sculpher M. An introduction to markov modelling for economic evaluation. Pharmacoeconomics 1998; 13 4:397-409; PMID:10178664; http://dx.doi.org/10.2165/00019053-199813040-00003
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ, Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making, 2003; 23 1:76-82; PMID:12583457; http://dx.doi.org/10.1177/0272989X02239651
   PubMed Web of Science ®Google Scholar
• Healthcare cost & Utilization Project (HCUP). Agency for healthcare research quality. http://www.ahrq.gov/data/hcup/
   Google Scholar
• Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Annal Internal Med, 2003; 138 12:960-8+I42; PMID:12809452; http://dx.doi.org/10.7326/0003-4819-138-12-200306170-00007
   PubMedGoogle Scholar
• Fry AM., Zell ER, Schuchat A, Butler JC, Whitney CG. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine 2002; 21 3-4:303-311; PMID:12450706; http://dx.doi.org/10.1016/S0264-410X(02)00451-6
   PubMedGoogle Scholar
• Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. J Am Med Association 2005. 294 16:2043-51; PMID:16249418; http://dx.doi.org/10.1001/jama.294.16.2043
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201 1:32-41
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378 9807:1962-73; PMID:21492929; http://dx.doi.org/10.1016/S0140-6736(10)62225-8
   PubMed Web of Science ®Google Scholar